Pre-eclampsia. Pre-eclampsia
Conditions
Interventions
Intervention 1: Intervention group: Two 80 mg aspirin tablets manufactured by Behstan Pharmaceutical Company and 3 ablet 10 mg dydrogesterone tablets manufactured by Behstan Pharmaceuticals are prescr
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Singleton pregnancies First trimester Doppler ultrasound at risk for uteroplacental perfusion disorders Have criteria for aspirin prescription (high-risk group: history of preeclampsia; autoimmune disease (systemic lupus erythematosus, antiphospholipid syndrome) Type 1 and 2 diabetes Multiple pregnancy Chronic hypertension Kidney diseases Obesity (body mass index > 30 kg/m2) Family history of preeclampsia (mother or sister) Age =35 years Previous history of low birth weight History of stillbirth Interwall between two pregnancies is more than 10 years. reproductive techniques including IVF
Exclusion criteria
Exclusion criteria: Fetal aneuploidies Fetal anomalies Bleeding disorders Women with allergies to aspirin or dydrogesterone Women who are currently taking aspirin or heparin for any other reason and women with normal, low-risk pregnancies who have a normal Doppler ultrasound smoking Mother's lack of cooperation in taking medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease fetal mortality and morbidity due to preeclampsia. Timepoint: After birth. Method of measurement: Vital Signs. | — |
Secondary
| Measure | Time frame |
|---|---|
| IUGR. Timepoint: 3rd trimester pregnancy. Method of measurement: Sonography.;Neonate weight. Timepoint: After birth. Method of measurement: scale.;NICU admission. Timepoint: After birth. Method of measurement: Clinical.;Neonate Apgar. Timepoint: One and five in the minute. Method of measurement: scoring. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFahime Zare
Shiraz University of Medical Sciences
Outcome results
None listed